Semaglutide plateau: why it happens and what the data show

Peptology · 2026-06-04

In short: what is „plateau“ in weight loss with Semaglutide?

„Plateau“ means that the rate of loss visibly slows or stops for weeks, and sometimes months — even though habits, dose or activity have not changed appreciably. This phenomenon is normal with almost all weight-reduction strategies (diets, medications, GLP-1 agonists, bariatric surgery). It results from both biological adaptation (the body „saves“ energy) and behavioral factors (small deviations that accumulate).

It is important to distinguish a „true plateau“ from the natural slowing of the weight-loss curve. In the large STEP trials with Semaglutide, average weight reduction accumulates over the first ~12–15 months, after which the curve becomes smoother, but benefits are maintained with continued therapy. In STEP-1 the mean change in weight to week 68 is −14.9% versus −2.4% with placebo, showing a strong effect, but the rate logically slows toward the end of the period.  In STEP-5 (104 weeks) the reduction is maintained around −15.2% with continued treatment, confirming that a „plateau“ is often a new equilibrium, not a failure. 

Why does a plateau happen? (biological and behavioral reasons)

1. Adaptive thermogenesis (metabolic adaptation). With weight loss, the body reduces energy expenditure more than predicted by the loss of lean mass. This is a proven mechanism behind plateaus and the tendency to „regain“ weight. 

2. Less „hidden expenditure“ (NEAT). Unconscious movement during the day (fidgeting, walking, general activity) drops during a calorie deficit. The body „economizes“ energy, lowering total daily expenditure.

3. A working but stabilized dose. Semaglutide is long-acting (t½ ~ 1 week), reaches steady-state in ~4–5 weeks and maintains a stable pharmacological effect with weekly dosing. This means that after titration the effect becomes predictable, and the rate of loss naturally slows as the „easily accessible“ reserves are exhausted. 

4. Tolerance/tolerability and real-world use. Gastrointestinal complaints can limit reaching or maintaining a maintenance dose, and interruptions (delayed injections, missed doses) „dilute“ the effect.

5. Set-point/biological „defense“ of weight. The body strives for a new equilibrium at the lower weight; appetite control improves with GLP-1, but counter-signals from other hormones strengthen over time — the result is slower subsequent progress.

6. Diabetes, comorbid conditions and medications. In T2D weight loss is on average more modest; some medications (e.g., steroids) work „against“ weight reduction.

7. Hydration, glycogen and cyclic retention. Daily fluctuations (salt, menstrual cycle, stress) can „mask“ the real trend for 2–4 weeks.

8. Behavioral „micro-slips“. After months of success small additions (caloric drinks, side dishes, frequency of „snacking“) return the energy balance close to zero — without a subjective sense of change.

What do clinical data say about the plateau with Semaglutide?

• STEP-1 (NEJM): −14.9% mean reduction at 68 weeks; it proceeds sustainably, but with a logical slowing of the rate toward the end — a characteristic „flattening“ of the curve, not an abrupt stop. 

• STEP-5 (2 years): With continuation of Semaglutide plus behavioral support the effect is maintained up to 104 weeks (−15.2% on average), which means the „plateau“ is more a stable lower weight while therapy continues. 

• STEP-4 (randomized withdrawal): After a 20-week run-in with ~−10.6% reduction, participants who continued Semaglutide lost an additional −7.9% by week 68; those who stopped regained +6.9% over the same period — a clear signal that interruption often leads to a „reverse trajectory“, not a plateau. 

• STEP-1 (extension after stopping): About 2/3 of lost weight is regained within 1 year after discontinuation (without active support), and some cardiometabolic benefits also regress toward baseline. This is not a „plateau“, but physiological catch-up in the absence of treatment. 

Conclusion: When Semaglutide is continued, the average curve shows sustained results and a slower but continuing reduction or maintenance. A „plateau“ most often represents an expected slowing plus metabolic adaptation — not a failure of the GLP-1 mechanism. 

Attention: The text is for educational purposes and does not replace medical consultation. Decisions about treatment/dosing should be made with a medical professional.

---

Frequently Asked Questions (FAQ)

1) Is a plateau typical in trials with Semaglutide?

Yes. Large trials show strong average weight loss and a natural slowing around months 12–15. This is expected and does not mean the drug has „stopped“ working. 

2) What happened after Semaglutide was stopped in the trials?

In STEP-4 and the STEP-1 extension, discontinuation was followed by partial regain of weight. In the data, a „plateau“ ≠ „lack of effect“; it rather reflects a new equilibrium at a lower weight while treatment continues. 

3) Why does weight loss vary between trial participants?

Individual differences (age, sex, baseline weight, T2D, medications, sleep/stress) and metabolic adaptation. This is typical for all weight interventions. 

4) Which combinations are being studied?

Combinations are in development (e.g. amylin + Semaglutide), which in trials show a greater mean weight reduction; they are still investigational. 

5) How long does Semaglutide „stay“ in the body?

Because of an approximately one-week half-life and strong albumin binding, the drug remains in circulation for weeks after a dose; steady-state is reached after ~4–5 weeks. 

Sources

• STEP-1 (NEJM): −14.9% at 68 weeks.

• STEP-5 (Nature Medicine): maintenance of ~−15% up to 104 weeks with continuation.

• STEP-4 (JAMA): after run-in, those who continued lost a further −7.9%, those who stopped gained +6.9% (week 20→68).

• STEP-1 extension: ~2/3 regained within 1 year after stopping. 

• Adaptive thermogenesis and plateau: review/guidance.   

• Pharmacokinetics (EMA): t½ ~ 1 week; steady-state in 4–5 weeks.

• Combinations in development (amylin + Semaglutide).